The primary objective of this study is to assess the correlation between the molecular profiles of non-small cell lung cancer (NSCLC) patients and indoor radon concentration, measured with an alpha-particle detector (a standardized and validated way of measuring indoor radon).

Approximately 975 patients diagnosed with NSCLC will be enrolled in 4 cohorts of this project:
· A: Driver-mutation group (EGFR, BRAF, MET, HER2 mutation)
· B: Driver-fusion group (ALK, ROS1, RET, NTRK1/2/3-rearrangements)
· C: WT-control group (absence of EGFR, BRAF, MET, HER2 mutation and ALK, ROS1, RET rearrangements in tissue assay)
· D: Other-control group (the rest of population included in the study)

After signing the informed consent, each patient will receive a study kit with an alpha-track detector to place in their home to measure indoor radon for 3 months, and a questionnaire to fill, including demographic data, home characteristics, smoking and environmental exposure, etc. After the period of measurement, the alpha-track detector will be sent to a central laboratory (Radonova) for the analysis.

The enrolment period will be 18 months, followed by 6 months for analysis and data interpretation.

The study will opened in more than 10 sites in the following 4 European countries: France, Spain, Italy, and Belgium.

We would like to thank all participating investigators for their initiative and we wish them best of luck with patient recruitment!